GenMark Diagnostics, Inc (GNMK) Holdings Boosted by Penn Capital Management Co. Inc.

Penn Capital Management Co. Inc. boosted its position in GenMark Diagnostics, Inc (NASDAQ:GNMK) by 56.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 543,715 shares of the medical equipment provider’s stock after acquiring an additional 196,150 shares during the quarter. Penn Capital Management Co. Inc.’s holdings in GenMark Diagnostics were worth $2,267,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of GNMK. Wrapmanager Inc. increased its position in shares of GenMark Diagnostics by 121.3% in the 4th quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after purchasing an additional 21,679 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of GenMark Diagnostics by 111.1% in the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 26,000 shares during the last quarter. OLD National Bancorp IN increased its position in shares of GenMark Diagnostics by 120.6% in the 4th quarter. OLD National Bancorp IN now owns 49,765 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 27,208 shares during the last quarter. FDx Advisors Inc. bought a new stake in shares of GenMark Diagnostics in the 3rd quarter worth about $231,000. Finally, Voya Investment Management LLC increased its position in shares of GenMark Diagnostics by 17.5% in the 2nd quarter. Voya Investment Management LLC now owns 19,725 shares of the medical equipment provider’s stock worth $233,000 after purchasing an additional 2,943 shares during the last quarter.

GenMark Diagnostics, Inc (GNMK) opened at $4.49 on Tuesday. GenMark Diagnostics, Inc has a 1 year low of $3.63 and a 1 year high of $13.67. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

Several research firms have recently weighed in on GNMK. Canaccord Genuity reissued a “buy” rating and issued a $14.00 target price on shares of GenMark Diagnostics in a research report on Monday, October 30th. Needham & Company LLC lowered their price objective on shares of GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Raymond James Financial reaffirmed a “market perform” rating on shares of GenMark Diagnostics in a research report on Friday, November 3rd. BidaskClub raised shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $11.80.

WARNING: “GenMark Diagnostics, Inc (GNMK) Holdings Boosted by Penn Capital Management Co. Inc.” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/genmark-diagnostics-inc-gnmk-holdings-boosted-by-penn-capital-management-co-inc.html.

GenMark Diagnostics Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc (NASDAQ:GNMK).

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply